The multivalent Cuban pneumococcal vaccine, Quimi-Vio, appears today in the first report of the World Health Organization (WHO) on immune preparations under development to prevent infections caused by antimicrobial-resistant bacteria..
According to the analysis, there are currently 61 candidate vaccines in various stages of clinical study to deal with diseases caused by pathogens within the list of bacteria that the entity classifies as priorities.
in this way, Antillean is included in a list published by the United Nations along with other preparations in clinical trials designed to combat pneumococci in countries such as the United States, United Kingdom, Switzerland, Austria, China and Brazil..
A few months ago, the director general of the Finlay Vaccine Institute, Dr. Vicente Ferrez, announced that a nationally produced vaccine is very close to being viable for children.
He said that as part of the intervention study, it was applied to children in Cienfuegos province (230 kilometers southeast of this capital), after which there was a significant reduction in respiratory infections in that area.
According to statements made by Daniel Garcia, Director of the Laboratory for Chemical and Biomolecular Synthesis at the Faculty of Chemistry of the University of Havana, to Prensa Latina, Production of Quimi-Vio is currently being resumed and its generalized clinical evaluation will soon begin.
actually said, They are several vaccines in one, fighting the seven strains of Streptococcus Pneumonia bacteria that cause pneumonia, meningitis and sepsis in children..
(taken from latin press)
other information:
Evaluation of medication in pregnant women with iron deficiency anemia
“Unapologetic tv specialist. Hardcore zombie trailblazer. Infuriatingly humble problem solver.”